Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04551482
PHASE2

Oxytocin for Weight Loss in Adolescents

Sponsor: Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in youths with obesity, ages 12-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (1 spray per nostril, 4 times per day) for 12 weeks. Study visits include screening to determine eligibility, 2-part main study visits at baseline, week 8, and week 12, and safety check-in visits at weeks 1, and 4; phone calls at weeks 2, 6, and 10, with a safety follow-up visit 6 weeks after the last dose of study drug. Study procedures include appetite, behavioral, metabolic, and endocrine assessments.

Official title: Oxytocin as a Neuroendocrine Therapy for Obesity in Youth

Key Details

Gender

All

Age Range

10 Years - 18 Years

Study Type

INTERVENTIONAL

Enrollment

75

Start Date

2021-07-28

Completion Date

2027-03-31

Last Updated

2025-07-20

Healthy Volunteers

No

Interventions

DRUG

Oxytocin nasal spray

24 IU nasal spray, 4 times per day for 12 weeks

DRUG

Placebo

24 IU nasal spray, 4 times per day for 12 weeks

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States